Ariel Yaar
VP R&D @ altshare
Los Angeles, United States
Ariel Yaar is a seed investor at altshare in Los Angeles focused on Software and Health Care. Ariel Yaar is the VP of Research and Development at altshare.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Ariel Yaar invests in
Stages Ariel Yaar invests in
Countries Ariel Yaar invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Software 2 (33%)
- Health Care 2 (33%)
- CRM 1 (17%)
- SaaS 1 (17%)
- Mobile 1 (17%)
Stage
- Seed 4 (67%)
- Series A 1 (17%)
- Series B 1 (17%)
Country
- Israel 2 (33%)
- United States 2 (33%)
- United Kingdom 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
DermaDetect
|
DermaDetect was co-founded a year ago by four experienced entrepreneurs and is clinically led by Prof. Arieh Ingber, former head of department of dermatology in Hadassa Medical Center in Israel, a world-renowned dermatologist.We've developed a diagnostics & treatment tool/app (Apple, Android, Web), which enables healthcareprofessionals and patients to self-triage & manage skin disorders. The underlying technology is based on the combination of two approaches: dermatological rule base inference & image analysis using machine learning.We’re in a progress of a pilot-study to validate the effectiveness of our technology within the Israeli Health system, which is world’s best sandbox for such a study.Funded by two angel investors, eHealth Ventures [and their partners: Maccabi Healthcare Services in Israel (second biggest HMO in Israel), the Cleveland Clinic (the second largest healthcare provider in the US), Amgen], and supported by the Israel Innovation Authority. | Seed / Aug 21, 2022 | |
|
DermaDetect
|
DermaDetect was co-founded a year ago by four experienced entrepreneurs and is clinically led by Prof. Arieh Ingber, former head of department of dermatology in Hadassa Medical Center in Israel, a world-renowned dermatologist.We've developed a diagnostics & treatment tool/app (Apple, Android, Web), which enables healthcareprofessionals and patients to self-triage & manage skin disorders. The underlying technology is based on the combination of two approaches: dermatological rule base inference & image analysis using machine learning.We’re in a progress of a pilot-study to validate the effectiveness of our technology within the Israeli Health system, which is world’s best sandbox for such a study.Funded by two angel investors, eHealth Ventures [and their partners: Maccabi Healthcare Services in Israel (second biggest HMO in Israel), the Cleveland Clinic (the second largest healthcare provider in the US), Amgen], and supported by the Israel Innovation Authority. | Series B / Jan 01, 2022 | |
BioChange Ltd.
|
BioChange has developed a breakthrough technology for tissue regeneration. | Series A / Aug 01, 2021 | |
GearEye
|
GearEye provides a gear management system for on-the-go professionals. It uses RFID tags, a phone, and a handheld Gear Scanner to prevent the loss and misplacement of valuable items. Their tracking system is based on RFID technology and tailored for freelancers and SMEs. | Seed / Sep 01, 2018 | |
Glassbox
|
Glassbox develops an analytics platform designed to automatically record, index, and analyze digital interactions.Formerly Clarisite, it empowers organizations to manage and optimize the entire digital lifecycle of their web and mobile customers. Leveraging unparalleled big data, behavioral analytics, and record-replay capabilities, Glassboxenables enterprises to see not only what online and mobile customers are doing but also why they are doing it. Most importantly, Glassbox informs and facilitates action based on those insights that can lead to enhanced customer experience, decreased customer disputes, and improved regulatory compliance. Its solutions are used by medium to very large enterprises mostly in the financial services and insurance industries but are equally relevant to the needs of a wide range of verticals including healthcare, telecommunications, utilities, gambling, and business services.The company was founded by Yaron Gueta, Hanan Blumstein, and Yoav Schreiber in 2010 and is headquartered in London, England. | Seed / Sep 01, 2014 | |
Readz
|
Readz: Beyond Websites and Blogs.Readz plays in the fast growing content marketing field and addresses the upcoming challenges for brands to be able to provide quality online content experiences beyond websites and blogs.Readz is a SaaS content creation platform. With Readz, brands can rapidly create beautiful online content, in particular:micro-sitesonline presentationsinteractive publications such as magazines, white papers and brochuresReadz offers designers and marketers an online drag-and-drop editing solution to create and publish responsive, mobile-friendly content that is instantly available to customers and prospects. | $4.5M / Seed / Feb 01, 2012 |
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Ariel Yaar invest in?
Ariel Yaar invests primarily in Software, Health Care and CRM startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ariel Yaar?
Public channels for Ariel Yaar include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ariel Yaar last invest?
The most recent investment recorded for Ariel Yaar closed in Aug 2022. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
